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accompanied by a decrease in serum sclerostin
levels
Elżbieta Skowrońska-Jóźwiak1,2, Kinga Krawczyk-Rusiecka1,2, Krzysztof C Lewandowski1,2,
Zbigniew Adamczewski1,2 and Andrzej Lewiński1,2*Abstract: Sclerostin, a product of a SOST gene, is a protein expressed by osteocytes that inhibits osteoblastic bone
formation. Several hormones, including PTH and glucocorticosteroids, have been suggested to be possible
regulators of sclerostin production. The influence of thyroid hormones on sclerostin synthesis has not been
investigated, so far. The aim of the study was to evaluate sclerostin concentrations in patients before and after
treatment of thyrotoxicosis.
Patients and methods: The study involved 15 patients (4 men), mean age 51.8±15.3 years, mean BMI value - 24.7
±3.5, with thyrotoxicosis due to Graves’ disease or toxic multinodular goitre. Serum sclerostin was measured by
immunoassay at diagnosis of thyrotoxicosis and after 6–10 weeks of treatment with thiamazole. The data were
analysed by means of simple descriptive statistics of location and dispersion and Mann–Whitney U test for pairs of
results, before and after thiamazole therapy. Association between variables was evaluated with use of Spearman`s
correlation coefficient.
Results: There was a significant decrease in free T3 (FT3) and free T4 (FT4) concentrations (from 8.74±4.79 pg/ml to
3.54±2.40 pg/ml, and from 4.48±2.21 ng/ml to 1.02±1.07 ng/ml, respectively, p<0.001). This was accompanied by a
marked decrease of serum sclerostin levels from 55.46±20.90 pmol/l to 35.73±15.70 pmol/l, p<0.0015). Interestingly,
enough, sclerostin levels did not correlate with serum FT3 or FT4 concentrations.
Conclusions: Restoration of a euthyroid state in patients with thyrotoxicosis results in a significant decrease in
serum sclerostin concentrations. The above mentioned phenomenon may reflect lowering of bone metabolism, but
a possible direct influence of thyroid hormones on SOST gene needs to be investigated.Background
Sclerostin, a product of a SOST gene, is a protein
expressed by osteocytes and inhibits osteoblastic bone for-
mation. Sclerostin deficiency has been implicated in the
pathogenesis of bone sclerosing dysplasias, i.e. sclerosteo-
sis and van Buchem disease [1]. Several hormones have
been suggested to serve as possible regulators of sclerostin
production. PTH decreased sclerostin production in vitro
in mice [2], as well as in vivo in humans [3]. On the other
hand, calcitriol alone or in combination with retinoic acid
increased SOST expression in human osteoblastic cells* Correspondence: alewin@csk.umed.lodz.pl
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distribution, and reproduction in any mediumin vitro [4]. Glucocorticoids are thought to stimulate scler-
ostin secretion from osteocytes [5].
The influence of thyroid hormones on sclerostin syn-
thesis has not been investigated so far, however the
influence of hypothalamus-pituitary-thyroid axis on
bone metabolism is well known [6]. Thyroid hormones
are necessary for normal growth. Population studies in-
dicate that both hypothyroidism and hyperthyroidism
are associated with an increased risk of fractures [7] .
The aim of the study was to evaluate sclerostin con-
centrations in patients before and after treatment of
thyrotoxicosis.Patients and methods
The study was approved by the Ethics Committee of the
Polish Mother's Memorial Hospital - Research Institute inMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Descriptive statistics for demographic
characteristics of the tested sample (n=15)
Mean Median SD Min Max p-value
Age [years] 51.8 59.0 15.3 18.0 69.0
Body mass - before [kg] 69.3 66.0 12.7 48.0 98.0 0.051
Body mass - after [kg] 70.5 72.0 12.1 51.0 98.0
BMI value - before [kg/m2] 24.7 23.8 3.5 1.5 1.9 0.033
BMI value - after [kg/m2] 25.2 25.4 3.4 19.6 31.7
Heigth 1.7 1.6 0.1 1.55 1.82 -
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mean age 51.8±15.3 years, mean value of BMI - 24.7±3.5
kg/m2, with thyrotoxicosis due to Graves’ disease or toxic
multinodular goitre. Characteristics of examined popula-
tion before and after treatment was shown in Table 1.
Serum sclerostin was measured by with a quantitative
sandwich ELISA by Biomedica (Vienna, Austria) at diag-
nosis of thyrotoxicosis and after 6–10 weeks of treatment
with thiamazole. The intraassay coefficient of variance
(CV) is 5%, and the interassay coefficient of variance (CV)
is 3–6%. The data were analysed by means of simple
descriptive statistics of location and dispersion and
Mann–Whitney`s U test for pairs of results before and
after thiamazole therapy. Association between variables
was evaluated with use of Spearman`s correlation
coefficient.Results
There was a significant decrease in FT3 and FT4 concen-
trations (from 8.74±4.79 pg/ml to 3.54±2.40 pg/ml, and
from 4.48±2.21 ng/ml to 1.02±1.07 ng/ml, respectively
p<0.001). This was accompanied by a marked decrease of
serum sclerostin levels from 55.46±20.90 pmol/l to 35.73
±15.70 pmol/l, p<0.0015) (Table 2). Interestingly, enough,Table 2 Descriptive statistics for the measurement results bef
both measurements)
Mean Median
anti-TPO – before [IU/ml] 222.7 21.8
anti-Tg – before [IU/ml] 109.2 20.2
anti-TSHR – before [IU/l] 7.6 1.3
anti-TSHR – after [IU/l] 11.9 10.9
TSH - before [mIU/l] 0.0 0.0
TSH – after [mIU/l] 1.1 0.0
FT3 – before [pg/ml] 8.74 7.53
FT3 – after [pg/ml] 3.49 3.54
FT4 – before [ng/ml] 4.48 2.21
FT4 – after [ng/ml] 1.02 1.07
Sclerostin- before [pmol/l] 55.46 41.90
Sclerostin – after [pmol/l] 35.73 27.20
P-value for the Mann–Whitney`s U test for a comparison of pairs of measurement reneither sclerostin nor TSH levels did not correlate with
serum FT3 or FT4 (Tables 3 and 4).
Discussion
We demonstrated high levels of sclerostin in thyrotoxi-
cosis and a significant decrease of its serum concentra-
tions coinciding with restoration of an euthyroid state.
Pretreatment sclerosin levels in our study were higher
than reference values presented by Biomedica (mean
concentration - 19.3 pmol/l, range from 10.9 pmol/l to
28.7 pmol/l in serum), and by other authors - 33–37
pmol/l for healthy premenopausal women [6,7] and 49.8
pmol/l - for men [7].
Thyrotoxicosis is a common endocrine disorder, affect-
ing several systems and organs including skeletal system.
Thyrotoxicosis increases bone metabolism and leads to
development of osteoporosis [8-10]. Hyperthyroid
patients have high bone turnover and negative calcium
and phosphorus balance [11]. These detrimental effects
of thyrotoxicosis on bone metabolism are probably
caused by overproduction of T3, mediated principally by
T3 receptor alpha [12] or low TSH level [13,14].
There are several examples of negative impact of thyr-
ototoxicosis on bones even, in subclinical hyperthyroid-
ism, for instance low-normal TSH values are associated
with high prevalence of vertebral fractures in women
with post-menopausal osteoporosis or osteopenia, inde-
pendently of thyroid hormones, age and BMD value
[13]. This is one of the reasons why in subclinical hyper-
thyroidism treatment should be considered in the pres-
ence of risk factors, including osteoporosis [15].
Influence of thyrotoxicosis on bone seems to be tempor-
ary. Fracture risk was only significantly increased around
the time of diagnosis but decreased to normal levels after
restoration of an euthyroid state [9,10]. Furthermore,
normalization of BMD, bone markers and osteoprotegerinore and after thiamazole therapy (not all subjects have
SD Min Max p-value
356.0 5 1000 -
222.7 10 803 -
11.6 0.3 40.0 0.999
5.9 6.6 18.3
0.0 0.0 0.0 0.013
1.7 0.0 5.8
4.79 4.02 16.5 0.0010
2.40 0.74 4.8
1.01 7.84 32.5 0.0010
0.44 0.34 1.7
20.90 39.29 148.8 0.0015
15.70 23.46 99.6
sults before and after antithyroid therapy (where appropriate).
Table 3 Spearman rang correlation coefficients (rs) for
FT3 (before and after) and other measurement results
FT3 - before FT3 - after
rs p-value rs p-value
TSH 0.535 0.040 −0.464 0.094
Sclerostin 0.079 0.781 0.064 0.829
Table 4 Spearman rang correlation coefficients (rs) for
FT4 (before and after) and other measurement results
FT4 - before FT4 - after
rs p-value rs p-value
TSH 0.252 0.365 −0.489 0.076
Sclerostin −0.004 0.990 0.240 0.409
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authors showed elevation of bone formation markers des-
pite normalization of thyroid hormones and TSH levels
[10,17]. We speculate that a decrease of sclerostin levels –
as observed by us - may be associated with normalization
of bone metabolism. It may also be argued that the above
mentioned decrease in sclerostin levels in patients reco-
vering from thyrotoxicosis might be mediated by PTH.
This is because a fall of PTH concentration was reported
in subjects with thyrotoxicosis [10,17], followed by an in-
crease during anti-thyroid treatment [11]. There are also
recent data demonstrating a decline of sclerostin concen-
trations by PTH. For instance, lowering of sclerostin levels
was demonstrated after injection of PTH [3] and in
patients with hyperparathyroidism [18,19]. Supposing the
normalization of thyroid hormones is accompanied by an
increase of PTH, one might argue that PTH per se might
be responsible for the decline of sclerostin concentrations
observed, in our study.
To the best of our knowledge, this study is the first in
which a clear decrease in sclerostin concentrations
resulting presumably from a decrease of thyroid function
has been demonstrated. The cause of this phenomenon
is, however, complex and requires further study.
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